Following Cathie Wood: Buy the dip in e-commerce giant Shopify, continue to heavily invest in 'AI + Healthcare', and take profits in semiconductor hardware stocks

Last night, driven by strong stocks in the AI industry chain such as storage and semiconductors, both the S&P 500 and Nasdaq indexes hit new all-time highs. At the close, the S&P 500 was up 0.81%, the Nasdaq rose 1.03%, and the Dow Jones Industrial Average gained 0.73%. On the geopolitical front, the U.S. government reiterated on Tuesday that the ceasefire agreement with Iran remains valid, easing market concerns about a large-scale conflict breaking out in the Middle East.

In this market condition, ARK's portfolio adjustment strategy is very clear: on the buying side, heavily investing in the e-commerce SaaS giant Shopify despite its weak earnings, $Shopify (SHOP.US)$ , and 'taking the opportunity to buy low' in genetic sequencing company GeneDx, $GeneDx Holdings (WGS.US)$ ; on the selling side, decisively taking profits at high levels from cloud computing service providers, $CoreWeave (CRWV.US)$ and chip giants, $Advanced Micro Devices (AMD.US)$ 。

Buying Direction: Making bold moves in e-commerce infrastructure, unafraid of earnings volatility and firmly betting on genetic big data.

On the day, ARK’s buying funds were mainly split into two directions: one part was accumulating core internet assets at lower prices, while the other was sticking to its long-term focus on cutting-edge biotechnology.

Buying the e-commerce giant Shopify at a low price $Shopify (SHOP.US)$, with a single-day purchase of up to 255,800 shares.On the news front, Shopify reported strong Q1 earnings performance, with core operating metrics surpassing expectations. However, the stock price fell against the market trend. The company also provided guidance for Q2, forecasting annual revenue growth of 25% to 30%. Meanwhile, Shopify is actively integrating AI into merchant tools. Despite concerns about short-term profit pressures, 'Cathie Wood' chose to make a significant move at this juncture, betting on its robust software ecosystem moat and the long-term profit elasticity brought by AI commercialization.

Firmly betting on 'AI + Healthcare', bought $GeneDx Holdings (WGS.US)$245,900 shares and $Intellia Therapeutics (NTLA.US)$214,200 shares.WGS's recently announced Q1 results showed that despite gross profit growth, net losses significantly widened to $63.3 million, and revenue also missed expectations. However, ARK took advantage of the negative earnings report to aggressively increase its position, a classic 'buying the dip'. In the eyes of institutional investors, WGS serves as an 'AI training database' holding nationwide rare disease data in the US, and its long-term data moat is far more strategically valuable than quarterly losses. Simultaneously increasing stakes in gene-editing newcomer NTLA further solidifies ARK's core position in the 'next-generation precision medicine' sector.。

Sell side: Profit-taking after semiconductor hardware sector earnings realization, continuing the biotech 'weeding out the weak and keeping the strong'

On the sell side, ARK's actions clearly reflect investment discipline in 'sector rotation' and 'optimizing capital efficiency'.

Reduced positions in cloud service providers $CoreWeave (CRWV.US)$totaling 98,900 shares.Benefiting from the explosive demand for AI large model training and inference, GPU cloud computing service providers represented by CoreWeave are rising rapidly. ARK chose to moderately reduce its position at this stage, aiming to secure profits earned earlier from 'infrastructure computing power' investments, and reallocate funds into the 'application layer,' which is more attractively valued and holds explosive potential.

Reduced holdings in chip giant $Advanced Micro Devices (AMD.US)$A total of 45,900 shares.With the accelerated growth of AI inference and intelligent agent applications, the demand for server CPU computing power is surging. AMD, with its high core count and multi-threading capabilities, perfectly fits AI's requirement for CPUs to be both fast and numerous. The company expects its market share in the total server CPU market to exceed 50%. ARK chose to sell during a period of sector optimism and heightened market sentiment, aiming to free up capital for investment in software and biotech sectors.

Sold single-cell sequencing equipment provider $10x Genomics (TXG.US)$37,200 shares, and continued to reduce holdings in synthetic biology company $Twist Bioscience (TWST.US)$8,215 shares.TXG will announce earnings on May 7th, with the market expecting its Q1 revenue to decline 6% year-over-year. ARK’s decision to reduce its position before earnings and continue selling TWST demonstrates strict enforcement of 'weeding out the weak and retaining the strong' within the biotech sector. For traditional hardware-heavy equipment stocks facing short-term earnings pressure, ARK decisively views them as assets dragging down portfolio efficiency and has been aggressively divesting.

Continued selling semiconductor automated testing equipment leader $Teradyne (TER.US)$A total of 21,500 shares.This is consistent with AMD's operational logic, representing a routine rotation move of withdrawing funds from the highly-valued semiconductor hardware sector.

Futubull [Opportunities page] Now featuring the ability to track portfolios of renowned investors! Choose from multiple celebrity holdings, follow the investment strategies of top players with one click, accurately target high-quality stocks, and invest with greater confidence!

124K Views